Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:SRPT). Here's what you need to know.
Arrowhead Pharmaceuticals Inc.（納斯達克：ARWR）的股票在週二上漲，此前該公司與Sarepta Therapeutics Inc.（納斯達克：SRPT）宣佈了一項全球許可和合作協議。以下是你需要知道的。
What To Know: The partnership grants Sarepta exclusive worldwide rights to Arrowhead's investigational RNA interference (RNAi) therapies for rare genetic diseases targeting muscle, the central nervous system (CNS) and the lungs.
要點：該合作伙伴關係授予Sarepta對Arrowhead用於治療針對肌肉、中樞神經系統（CNS）和肺部的稀有遺傳疾病的實驗性RNA干擾（RNAi）療法的全球獨家權利。
The agreement focuses on Arrowhead's Targeted RNAi Molecule platform, which enables precise delivery of therapies designed to reduce the activity of disease-causing genes.
該協議側重於Arrowhead的靶向RNAi分子平台，該平台能夠精確地遞送旨在減少致病基因活性的療法。
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.
Arrowhead將獲得50000萬美元的預付款，以及Sarepta以35%的溢價進行的32500萬美元股權投資。其他條款包括在五年內支付的25000萬美元，將在5000萬美元的分期付款中支付，以及在未來一年內最多30000萬美元的短期里程碑付款和潛在的商業銷售分級版稅。
Arrowhead CEO Christopher Anzalone called the agreement transformative, noting that the influx of capital extends the company's financial runway through 2028. This timeline positions Arrowhead to pursue the commercial launch of its first product, plozasiran, pending regulatory approval.
Arrowhead首席執行官Christopher Anzalone稱該協議具有變革性，指出資本的流入將公司的財務承受能力延長至2028年。這一時間表使Arrowhead能夠在監管批准後追求其首個產品plozasiran的商業發佈。
Sarepta sees the collaboration as a strategic expansion of its portfolio, complementing its expertise in gene therapy and Duchenne muscular dystrophy. Sarepta CEO Doug Ingram highlighted the potential for these RNAi programs to have a significant market impact. As part of the agreement, Ingram will join Arrowhead's Board of Directors.
Sarepta將此次合作視爲其組合的戰略擴展，補充其在基因治療和杜氏肌營養不良症方面的專業知識。Sarepta首席執行官Doug Ingram強調，這些RNAi項目對市場產生重大影響的潛力。作爲協議的一部分，Ingram將加入Arrowhead的董事會。
"The agreement affords multiple potential blockbuster opportunities, serves our strategic priorities for the remainder of the decade and beyond and diversifies our business model across one-time therapies and chronic treatments allowing for long-term growth and success," Ingram said.
「該協議提供了多個潛在的塊頭型機會，符合我們在本十年內及更長時期的戰略優先事項，並多元化了我們的業務模式，涵蓋一次性療法和慢性治療，從而允許長期增長和成功，」Ingram說。
The collaboration is expected to close in early 2025, pending regulatory approval. Both companies have emphasized the agreement's significance in advancing treatments for rare genetic diseases, with additional details anticipated in their upcoming investor presentations.
該合作預計將在2025年初完成，待監管批准。兩家公司都強調了該協議在推動稀有遺傳疾病治療方面的重要性，期待在他們即將進行的投資者演示中提供更多細節。
ARWR Price Action: Arrowhead Pharmaceuticals shares were up 16.7% at $21.94 at the time of writing, according to Benzinga Pro.
ARWR價格走勢：根據Benzinga Pro的數據，arrowhead pharmaceuticals的股票在撰寫時上漲了16.7%，達到21.94美元。
- Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M
- 合併中的Berry Global同意以約5.4億美元出售特種膠帶部門
Image Via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。
